About
OMEICOS develops therapies targeting mitochondrial, cardiovascular, and inflammatory diseases by leveraging omega-3 fatty acid metabolism; its lead compound OMT-28 is advancing into Phase 3 clinical trials for Primary Mitochondrial Disease.
Explore OMEICOS's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.